A Microbicide is any substance or process that kills germs (bacteria, viruses, and other microorganisms that can cause infection and disease). Also called germicide.
The product has proven efficiency in lab tests, although clinical trials are yet to be performed. After discovering that silver nanoparticles are capable of blocking the entry of Human Immunodeficiency Virus (HIV) into the organism, a group of researchers from the University of Texas, in collaboration with Humberto Lara Villegas, specialist in nanoparticles and virology from the University of Monterrey, Mexico (UDEM), create a vaginal cream to control the transmition of the virus.
AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
The Population Council today announced it was awarded a cooperative agreement from the US Agency for International Development's (USAID) Office of HIV and AIDS: "Non-ARV Based Combination Microbicide that Blocks HIV and Other STIs."
With funding of $70 million to support its effort into 2021, the Microbicide Trials Network (MTN) will continue to develop and test products that aim to reduce the spread of HIV, the virus that causes AIDS, federal officials announced yesterday.
Principal investigators and clinical trials units have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Total funding for the networks' leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.
Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).
The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID).
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers today announced the launch of a global Phase II clinical trial of a potential rectal microbicide.
Pinning down an effective way to combat the spread of the human immunodeficiency virus, the viral precursor to AIDS, has long been challenge task for scientists and physicians, because the virus is an elusive one that mutates frequently and, as a result, quickly becomes immune to medication.
Recent breakthroughs in HIV prevention research have confirmed the promise of new options to help end the AIDS epidemic and highlight the urgent need for ongoing research to develop additional prevention options and support rapid rollout of proven ones.
A reformulated version of an anti-HIV gel developed for vaginal use was found safe and acceptable by HIV-negative men and women who used it rectally, according to a Phase I clinical trial published today in PLOS ONE.
Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.
"Results of a major HIV prevention trial suggest that daily use of a product -- whether a vaginal gel or an oral tablet -- does not appear to be the right approach for preventing HIV in young, unmarried African women," a press release from the Microbicide Trials Network reports.
Three antiretroviral-based strategies intended to prevent HIV infection among women did not prove effective in a major clinical trial in Africa.
Scientists who study HIV are facing a troubling consequence of their own success. They created drugs that can now give infected patients almost normal life expectancy. However, those same drugs will eventually cause the constantly mutating virus to evolve into a form that eludes current treatments.
International Rectal Microbicide Advocates (IRMA), the Population Council, and the Microbicide Trials Network (MTN) today released a collaborative video project called "The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials." The jointly produced video, the first of its kind, is designed to educate communities affected by HIV about rectal microbicide development and the importance of participating in clinical trials to help speed the search for new HIV prevention options.
BBC News examines ongoing efforts to develop a female-controlled microbicide to prevent HIV infection. But so far, "efforts ... have presented a great deal of frustration in the fight against this global epidemic," the news service writes, detailing the history of some failed experiments.
In this post in the Center for Global Health Policy's "Science Speaks" blog, IAVI President and CEO Margaret McGlynn, AVAC Executive Director Mitchell Warren and UNAIDS Executive Director Michel Sidibe highlight the release of a report from the HIV Vaccine & Microbicides Resource Tracking Working Group.
A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.